Predict your next investment

Corporation
mtpconnect.org.au

See what CB Insights has to offer

Investments

3

Partners & Customers

8

About MTPConnect

MTPConnect is a medical technologies and pharmaceuticals industry growth center in Australia. MTPConnect casts a commercial eye on all aspects of the medical technology and pharmaceutical industries and identifies players with the ability to develop products and services that will drive jobs in Australia. The aim for MTPConnect is to boost the sector's competitive advantage and establish Australia as an Asia Pacific hub for medical technology and pharmaceutical companies by identifying opportunities to reduce regulatory burden, increasing collaboration and commercialization, improving capabilities to engage with international markets and global supply chains, and enhancing management and workforce skills.

MTPConnect Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest MTPConnect News

Ear Science Institute Australia Receives $993K Grant for ClearDrum Ear Implant

Aug 10, 2020

Ear Science Institute Australia Receives $993K Grant for ClearDrum Ear Implant MTPConnect and the Minister for Health, The Hon Greg Hunt MP, announced $18.8 million in funding for 21 early stage medical technology projects across Australia, according to a press release on the Ear Science Institute Australia’s (ESIA) website . One of those recipients is ESIA, who received a $993,500 grant to advance the commercialization of ClearDrum, a device that incorporates silk in an ear implant. ClearDrum has been developed in Western Australia and has been driven by ESIA Founding Director Professor Marcus Atlas. It is a “world-first, acoustically optimized” silk fibroin implant for the treatment of chronic middle ear disease (CMED). It is the “first implant which mimics a human eardrum,” according to ESIA’s announcement. ESIA say that “while it looks like a contact lens, it’s instead a device on which the patient’s cells can grow.” “What our team found is that the tympanic membrane cells, called keratinocytes, actively proliferate and migrate across this scaffold, promoting the healing process,” said Atlas. “This is a major step for ESIA as we move to translate our research science to the world.” The device is developed in two different formulations, which will allow ClearDrum to dissolve over time, addressing small perforations or acting as a long lasting implant for larger perforations, with no need for further operations. Additionally, the transparent material “enables ongoing monitoring of healing and resolution of the middle ear,” ESIA says. The World Health Organization (WHO) estimates that 65-330 million individuals have CMED, and 60% of them have a significant hearing impairment. ClearDrum will help provide “a novel and effective treatment for sufferers of CMED, which is a major cause of global disability in ear surgery practice and is particularly prevalent in Australian indigenous populations.” ESIA Chief Executive Officer Sandra Bellekom adds, “Our plan is for ClearDrum to be available to patients in a clinical trial next year. Without funding such as this from MTPConnect, that opportunity for the end user to benefit from our breakthrough research would be a lot further away.” Atlas worked with lead scientist Dr Filippo Valente on the successful grant. Valente said, “Current treatments leave a significant percentage of individuals with ongoing problems, often requiring multiple surgeries and incurring high costs for the healthcare system. The ClearDrum device aims to provide an off-the-shelf, near-permanent implant, to resolve these difficulties in a single, straightforward surgical procedure.” The current stage of development of the project includes a working prototype, a strong international IP position, a contracted manufacturer organization, and collaborations with a series of Australian companies and organizations to address various phases of pre-clinical and clinical development. This new BMTH funding will assist with the commercialization phase. MTPConnect Managing Director and CEO, Dr Dan Grant, says round three of the BioMedTech Horizons program focused predominantly on research funding for digital health innovations and medical devices. “Building home-grown translational and commercialization capacity means boosting our knowledge economy and creating new products, jobs, and potential exports. This is particularly important now considering the hit that our sector has taken dealing with the impact of the COVID-19 pandemic and lockdown,” said Grant. Source: ESIA

MTPConnect Investments

3 Investments

MTPConnect has made 3 investments. Their latest investment was in Ear Science Institute Australia as part of their Grant on August 8, 2020.

CBI Logo

MTPConnect Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/10/2020

Grant

Ear Science Institute Australia

$1M

Yes

1

8/3/2020

Grant

Subscribe to see more

$99M

Subscribe to see more

10

7/23/2020

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/10/2020

8/3/2020

7/23/2020

Round

Grant

Grant

Grant - II

Company

Ear Science Institute Australia

Subscribe to see more

Subscribe to see more

Amount

$1M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

MTPConnect Partners & Customers

8 Partners and customers

MTPConnect has 8 strategic partners and customers. MTPConnect recently partnered with BioCurate on February 2, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

2/18/2019

Partner

Australia

New UniQuest partnership set to bridge the biomedical translation funding gap - UniQuest - The University of Queensland, Australia

`` In this partnership with MTPConnect and BioCurate we 'll draw on our commercialisation and drug discovery expertise to help develop Australian technologies to the stage where they can attract further capital and support , bridging the funding gap and giving the country 's ground-breaking medical research the best opportunity to create change in the lives of people in Australia and around the world , '' Dr Moss said .

1

2/14/2019

Partner

Australia

Subscribe to see more

Subscribe to see more

10

10/26/2018

Partner

Australia

Subscribe to see more

Subscribe to see more

10

7/3/2018

Partner

Australia

Subscribe to see more

Subscribe to see more

10

11/2/2017

Partner

Australia

Subscribe to see more

Subscribe to see more

10

Date

2/18/2019

2/14/2019

10/26/2018

7/3/2018

11/2/2017

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Australia

Australia

Australia

Australia

Australia

News Snippet

New UniQuest partnership set to bridge the biomedical translation funding gap - UniQuest - The University of Queensland, Australia

`` In this partnership with MTPConnect and BioCurate we 'll draw on our commercialisation and drug discovery expertise to help develop Australian technologies to the stage where they can attract further capital and support , bridging the funding gap and giving the country 's ground-breaking medical research the best opportunity to create change in the lives of people in Australia and around the world , '' Dr Moss said .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.